Last reviewed 2026-04-23 · How we verify

CD-LD CR

CD-LD CR is a controlled-release formulation of a central nervous system stimulant.

CD-LD CR is a controlled-release formulation of a central nervous system stimulant. Used for Attention Deficit Hyperactivity Disorder (ADHD).

At a glance

Mechanism of action

CD-LD CR is a central nervous system stimulant that works by increasing the levels of certain neurotransmitters in the brain, such as dopamine and norepinephrine, which helps to improve attention and reduce impulsivity.

Approved indications

• Attention Deficit Hyperactivity Disorder (ADHD)

Common side effects

• Nausea
• Headache
• Insomnia
• Dizziness
• Dry mouth

Key clinical trials

• A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations (PHASE3)
• Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease (PHASE2)
• Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease (PHASE1, PHASE2)
• Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease Patients (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• CD-LD CR CI brief — competitive landscape report
• CD-LD CR updates RSS · CI watch RSS
• Impax Laboratories, LLC portfolio CI